Atea Pharmaceuticals, Inc.
For the period ended Jun 30, 2025. Filed Aug 7, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2025 · Filed Aug 7, 2025
AVIR$4.20-4.8%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(in thousands)
| Six Months EndedJune 30, | ||
|---|---|---|
| 2025 | 2024 | |
| Cash flows from operating activities | ||
| Net loss | $(71,433) | $(103,691) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Stock-based compensation expense | 11,618 | 25,306 |
| Depreciation and amortization expense | 208 | 208 |
| Accretion of premium and discounts on marketable securities | (3,061) | (6,512) |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other current assets | 1,743 | 8,194 |
| Other assets | (4,197) | — |
| Accounts payable | 4,386 | 1,218 |
| Accrued expenses and other liabilities | (2,602) | (6,703) |
| Operating lease liabilities | (95) | (87) |
| Net cash used in operating activities | (63,433) | (82,067) |
| Cash flows from investing activities | ||
| Purchases of marketable securities | (223,368) | (174,460) |
| Sales and maturities of marketable securities | 324,266 | 355,948 |
| Net cash provided by investing activities | 100,898 | 181,488 |
| Cash flows from financing activities | ||
| Proceeds from issuance of common stock under ESPP | 138 | 150 |
| Repurchase of common stock | (14,093) | — |
| Issuance of restricted stock units | (485) | — |
| Net cash (used in) provided by financing activities | (14,440) | 150 |
| Net increase in cash and cash equivalents | 23,025 | 99,571 |
| Cash and cash equivalents at the beginning of period | 64,696 | 143,823 |
| Cash and cash equivalents at the end of period | $87,721 | $243,394 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.